About Calsequestrin-1
Calsequestrin-1 (CASQ1) is a protein
from Homo sapiens identified by UniProt accession
P31415, 396 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Calsequestrin-1 |
| UniProt accession | P31415 |
| Gene | CASQ1 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (120)
Diseases linked to this target (Open Targets).
- myopathy due to calsequestrin and SERCA1 protein overload · score 0.61
- myopathy, tubular aggregate, 1 · score 0.46
- tubular aggregate myopathy · score 0.38
- grip strength measurement · score 0.30
- genetic disorder · score 0.19
- myopathy · score 0.13
- body fat percentage · score 0.09
- Distal myopathy, Nonaka type · score 0.05
- paramyotonia congenita of Von Eulenburg · score 0.05
- autosomal recessive limb-girdle muscular dystrophy type 2L · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31415-F1 | alphafold | PREDICTED | 89.99 | — |
Amino-acid sequence (396 residues)
MSATDRMGPR AVPGLRLALL LLLVLGTPKS GVQGQEGLDF PEYDGVDRVI NVNAKNYKNV FKKYEVLALL YHEPPEDDKA SQRQFEMEEL ILELAAQVLE DKGVGFGLVD SEKDAAVAKK LGLTEVDSMY VFKGDEVIEY DGEFSADTIV EFLLDVLEDP VELIEGEREL QAFENIEDEI KLIGYFKSKD SEHYKAFEDA AEEFHPYIPF FATFDSKVAK KLTLKLNEID FYEAFMEEPV TIPDKPNSEE EIVNFVEEHR RSTLRKLKPE SMYETWEDDM DGIHIVAFAE EADPDGFEFL ETLKAVAQDN TENPDLSIIW IDPDDFPLLV PYWEKTFDID LSAPQIGVVN VTDADSVWME MDDEEDLPSA EELEDWLEDV LEGEINTEDD DDDDDD
Explore Calsequestrin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets